CEO Under Fire for $89,000 Drug Has a History of Steep Price Hikes
- Sanders, Cummings requested information on increases in 2014
- Marathon CEO led company that hiked price on babies’ drug
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
The CEO of the latest drugmaker to face criticism over a product’s high price has a history of steep hikes on other drugs and at past companies.
Marathon Pharmaceuticals LLC Chief Executive Officer Jeffrey Aronin, under fire for setting an $89,000 price on the company’s drug for a rare, deadly muscle disease, was questioned in a letter more than two years ago by Washington lawmakers about mark-ups on two heart drugs. Years earlier, as the leader of another company, Aronin took high price increases on a drug used to treat babies with a congenital defect.